SciELO - Scientific Electronic Library Online

vol.28 issue4Mutations in the HFE gene (C282Y, H63D, S65C) in a Brazilian populationLaboratorial evaluation of molecular toxicity in thalassemic erythrocytes author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista Brasileira de Hematologia e Hemoterapia

Print version ISSN 1516-8484On-line version ISSN 1806-0870


HALLACK NETO, Abrahão E. et al. Risk stratification of large B-cell lymphomas. Rev. Bras. Hematol. Hemoter. [online]. 2006, vol.28, n.4, pp.296-300. ISSN 1806-0870.

Diffuse large B-cell lymphoma is a heterogeneous clinical pathological entity which accounts for about 30% to 35% of all non-Hodgkin's lymphoma cases. It is considered to be aggressive due to the patient's short survival time when incorrect treatment is provided. Since 1993, treatment has been carried out according to IPI, which has been validated in several studies. However, since there are different responses from patients with the same IPI submitted to similar therapies, new prognostic markers are needed for these patients. As the biological nature of such lymphomas is becoming better known, other variables are starting to be used in order to stratify risk. In this review we will approach the key biological markers used as prognostic factors to treat diffuse Large B-Cell Lymphoma patients.

Keywords : Large cell lymphoma; prognosis; review.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License